Overview

Ketek in CAP / AECB in Ambulatory Adult Patients

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

To determine the clinical effectiveness of telithromycin in the treatment of either CAP or AECB in a large population of ambulatory adult patients in a community-based setting.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Telithromycin